<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily Bergsland, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with Zollinger-Ellison syndrome (ZES) have gastrin-secreting tumors and the associated clinical consequences. This disorder can occur sporadically, or as a manifestation of multiple endocrine neoplasia type 1 (MEN 1), which accounts for approximately 25 percent of cases [<a href="#rid1">1</a>]. Medical therapy is the current standard of care for most patients with ZES as part of the MEN 1 syndrome. By contrast, many patients with sporadic ZES are candidates for surgical therapy. (See  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a> and <a class="local">'Surgery'</a> below.)</p><p>Prior to the development of effective acid suppression therapy, the major morbidity and mortality of ZES were related to complications of fulminant peptic ulcer disease; total gastrectomy was the only effective measure to protect patients from these problems [<a href="#rid2">2</a>].</p><p>The development of H2 antagonists and the more powerful proton pump inhibitors has resulted in a significant decrease in morbidity and mortality from ulcer disease and has obviated the need for gastrectomy [<a href="#rid3">3</a>]. Of 212 patients with ZES studied prospectively for a mean of 13.8 years, a ZES-related cause of death could be identified in only one-half of the 31 percent who died. All of the ZES-related deaths were due to tumor spread; none were due to hypersecretory complications [<a href="#rid4">4</a>].</p><p>This topic review will discuss the two current goals of therapy in ZES [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Control of the complications resulting from autonomous release of gastrin</p><p class="bulletIndent1"><span class="glyph">●</span>Control of the tumor itself</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MEDICAL MANAGEMENT</span><span class="headingEndMark"> — </span>The goal of medical management in Zollinger-Ellison syndrome (ZES) is to limit the clinical manifestations and complications of peptic ulcer disease. Because peptic symptoms in patients with ZES are often a poor marker of acid secretion, formal acid secretory studies have been advocated to guide the dosage of acid suppressants, with the goal of reducing gastric acid secretion to below 10 mEq/h prior to the next dose [<a href="#rid6">6</a>]. However, such studies are often not available even in major medical centers, and it has become customary among many gastroenterologists to initiate and maintain proton pump inhibitors at high dosage, using symptoms alone as a signal to increase the dose. To the author's knowledge, there have been few if any episodes of major peptic diathesis associated with this approach.</p><p class="headingAnchor" id="H3"><span class="h2">Proton pump inhibitors</span><span class="headingEndMark"> — </span>Proton pump inhibitors (eg, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>, <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a>, <a class="drug drug_general" data-topicid="9074" href="/d/drug information/9074.html" rel="external">dexlansoprazole</a>, <a class="drug drug_general" data-topicid="9474" href="/d/drug information/9474.html" rel="external">pantoprazole</a>, <a class="drug drug_general" data-topicid="9519" href="/d/drug information/9519.html" rel="external">rabeprazole</a>, and <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a>) effectively block acid secretion by irreversibly binding to and inhibiting the hydrogen/potassium ATPase that resides on the luminal surface of the parietal cell. (See  <a class="medical medical_review" href="/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders"</a>.) </p><p>Their effects last for more than 24 hours; as a result, many patients can be treated with a once a day regimen [<a href="#rid6">6</a>]. </p><p>Patients with ZES should be started on a high dose of a PPI (eg, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> 40 mg twice daily, <a class="drug drug_general" data-topicid="9474" href="/d/drug information/9474.html" rel="external">pantoprazole</a> 80 mg twice daily) [<a href="#rid5">5,7,8</a>]. PPIs have been generally safe, even when used in high doses. Some patients require an early upward titration of these doses; however, once control of acid output has been achieved, a gradual dose reduction is usually possible [<a href="#rid9">9</a>]. In a study of 37 patients who had received high-dose omeprazole for almost two years, nearly 50 percent were able to titrate the maintenance dose down to 20 mg daily [<a href="#rid10">10</a>]. Overall, 95 percent of patients without MEN 1, severe gastroesophageal reflux, or previous partial gastrectomy had safe reductions in their medication dose. PPIs are generally well tolerated and can control hypergastrinemia in ZES for &gt;10 years (although some patients experience low vitamin B12 levels) [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Adverse effects'</a>.)</p><p>H2-receptor antagonists are used less frequently and are not first choice, given a failure rate of 50 percent. When used, the dose is usually four to eight times the dose recommend for peptic ulcer disease [<a href="#rid1">1</a>].</p><p>When PPIs are unable to control gastric acid secretion, somatostatin analogs such as <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> can inhibit secretion of gastrin [<a href="#rid13">13,14</a>]. However, due to the unpredictability of the response and requirement for parenteral administration, they are not first-line agents for symptomatic patients with hypergastrinemia.</p><p class="headingAnchor" id="H4"><span class="h1">SURGERY</span><span class="headingEndMark"> — </span>Eighty percent of curable gastrinomas lie within the gastrinoma triangle comprised of the head of the pancreas and the duodenal sweep. Sporadic gastrinomas are often solitary and &gt;2 cm and located in the pancreas; tumors arising in the setting of MEN 1 most commonly arise in the duodenum and are typically small (&lt;2 cm) and multiple [<a href="#rid15">15</a>]. The combination of preoperative localization techniques, including contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and somatostatin receptor positron emission tomography (SSTR PET) [<a href="#rid1">1</a>], makes it possible for the experienced surgeon to identify over 90 percent of sporadic gastrinomas [<a href="#rid5">5,16</a>]. Intraoperative ultrasound or transduodenal illumination and duodenotomy are of particular value in detecting very small gastrinomas arising in the wall of the duodenum [<a href="#rid1">1,17,18</a>]. Of note, radio-guided surgery (wherein the surgeon uses a handheld radiation detector to localize tissues that have been "tagged" with a radioactive material) is an emerging technique that may improve intraoperative lesion detection (especially in gastrointestinal neuroendocrine tumors), but the optimal tracer and other technical details have not been established, and the overall impact on clinical outcomes remains unclear [<a href="#rid19">19</a>].</p><p>Patients with a sporadic gastrinoma who do not have evidence of metastatic spread of disease should be offered exploratory laparotomy and resection with curative intent, even in the event of negative imaging studies (which occurs in approximately 17 percent of patients) [<a href="#rid2">2,5,17,20</a>]. This recommendation stems from the fact that 60 to 90 percent of gastrinomas are malignant and, in addition to eliminating (or at least decreasing) the need for antisecretory medical therapy, successful resection of sporadic gastrinomas protects against the possibility of eventual morbidity and death from metastatic spread of the tumor (see below). The likelihood for surgical cure is especially high for extrapancreatic gastrinomas (eg, those in the duodenum or peripancreatic lymph nodes). In the hands of an experienced surgeon, up to 50 percent of these patients will be cured [<a href="#rid20">20,21</a>]. Published reports suggest a 10-year disease-free survival of 25 to 50 percent, 20-year overall survival of 58 to 71 percent, and 20-year disease-related survival of 73 to 88 percent [<a href="#rid17">17,22</a>]. Removal of the primary tumor also appears to reduce the risk of liver metastases [<a href="#rid20">20,23,24</a>]. Lymphadenectomy with removal of more than 10 lymph nodes at the time of surgery has been shown to achieve a higher biochemical cure as compared with selective or no lymphadenectomy [<a href="#rid25">25,26</a>]. The number of positive lymph nodes (or lymph node ratio) appears to have prognostic significance in gastrinoma and other panNETs. Recognizing the potential for cure in patients undergoing complete tumor removal (particularly with modern imaging tools and our ability to control acid hypersecretion throughout the perioperative period), the merits (and risks) of surgery need to be considered in the context of the life expectancy and co-morbidities of each patient [<a href="#rid11">11</a>]. In the unlikely event that a sporadic gastrinoma cannot be identified at surgery, we suggest deferring a Whipple's procedure in favor of closure, with the intent of serial imaging every six months to try to localize the neoplasm [<a href="#rid27">27</a>].</p><p>In contrast to sporadic tumors, laparotomy is not routinely recommended for patients with Zollinger-Ellison syndrome (ZES) as part of MEN 1 since the multifocal nature of the tumors in this disorder almost uniformly precludes cure of gastrin hypersecretion [<a href="#rid5">5,21</a>] (see  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a>). However, because a minority of MEN 1 tumors can have aggressive growth patterns, some recommend imaging techniques or even surgical exploration to identify those exceeding 2 cm with the intent of resecting them. Furthermore, other groups have taken a more aggressive approach in MEN 1 patients with gastrinomas (especially to control acid secretion), pursuing surgical resection based on imaging (including SSTR PET imaging) with or without localization with the selective arterial secretagogue injection test to achieve a biochemical cure [<a href="#rid28">28-30</a>]. </p><p>Enucleation is preferred when feasible in ZES, but local resection is often required for pancreatic head lesions and a distal pancreatectomy may be necessary for large tail lesions [<a href="#rid11">11</a>]. Whipple resections (pancreaticoduodenectomy [PD]) are not routine in ZES, but are reserved for pancreatic head or duodenal lesions that cannot be removed by enucleation [<a href="#rid29">29,30</a>]. The debate is ongoing, however, with some suggesting that initial PD is the superior initial surgical procedure for ZES in setting of MEN 1 [<a href="#rid30">30</a>] and others reserving PD for control of hormone secretion and removal of large tumors in the setting of MEN 1 [<a href="#rid29">29</a>]. In such cases, the potential benefits of PD, including improved lymph node retrieval, need to be weighed against the risks of complications from the Whipple procedure. </p><p>Laparoscopic surgery is controversial in ZES compared with other panNETs, owing to the need for more extensive exploration of the gastrinoma triangle, lymphadenectomy, and duodenectomy in many cases [<a href="#rid11">11</a>]. A minimally invasive approach may be reasonable, however, in the setting of a pancreatic tail gastrinoma occurring in the setting of MEN 1 [<a href="#rid11">11</a>] (see  <a class="medical medical_review" href="/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>). Endoscopic resection is usually reserved for highly selected cases (eg, duodenal lesion &lt;1 cm, limited to submucosa without lymph node involvement), but the risk of missing micrometastatic disease must be considered [<a href="#rid1">1</a>] and identifying such small tumors can be challenging.</p><p>Gastric secretion may not return to the normal range following gastrinoma resection because of a residual excess of gastric parietal cells, a consequence of the trophic effect of chronically elevated gastrin levels. Up to 40 percent of patients will require prolonged antisecretory therapy to control hyperacidity following curative resection, and such patients need continued monitoring for acid hypersecretion [<a href="#rid31">31,32</a>]. Of 50 patients who underwent curative resection for ZES, gastric hypersecretion was observed for a mean of eight years in 62 percent of patients and was judged to be extreme in 28 percent despite normal blood gastrin levels [<a href="#rid33">33</a>].</p><p>A parietal cell (proximal gastric) vagotomy performed at the time of tumor resection has been advocated to reduce (and in some cases obviate) the need for postoperative medical therapy, particularly when complete resection of the gastrinoma tissue cannot be accomplished [<a href="#rid31">31,34</a>]. However, it is currently uncommonly performed because of the efficacy of proton pump inhibitors. Furthermore, relatively few surgeons currently perform this procedure.</p><p>The reduction in mortality associated with surgical therapy for patients without metastatic disease was illustrated in a prospective study of 124 patients with gastrinoma presumed to be free of metastasis by imaging studies [<a href="#rid24">24</a>]. Only 3 percent of the 98 patients who underwent resection developed liver metastases during a mean follow-up period of 6.3 years [<a href="#rid24">24</a>]. By contrast, 23 percent of 26 patients treated medically developed metastatic disease over a slightly longer follow-up period (8.7 years). Two deaths due to metastatic gastrinoma occurred in the medically treated group compared with no disease-specific deaths in the operative group.</p><p class="headingAnchor" id="H5"><span class="h2">Reoperation for recurrence</span><span class="headingEndMark"> — </span>Although surgery decreases the incidence of hepatic metastases and improves survival, long-term biochemical cure is achieved in less than 30 percent. Reoperation may be of benefit in those with recurrent ZES in whom the tumor can be identified and localized. In one study, for example, 17 patients with recurrent disease that was unequivocally imaged underwent 18 reoperations [<a href="#rid35">35</a>]. Five patients were disease free after operation, with a median follow-up of 28 months. There were no deaths in the cured group; two patients in the group with persistent disease died during a median follow-up of 34 months [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H6"><span class="h1">RADIATION THERAPY FOR NONSURGICAL CANDIDATES</span><span class="headingEndMark"> — </span>Experience with external beam radiotherapy (RT) in the management of gastrinomas is limited. Although pancreatic neuroendocrine tumors were previously considered to represent a radioresistant neoplasm, data from published case reports and small case series suggest that RT can produce high rates of symptomatic palliation and freedom from local progression in patients who are not candidates for surgical resection [<a href="#rid37">37-43</a>].</p><p class="headingAnchor" id="H7"><span class="h1">THERAPY OF METASTATIC DISEASE</span><span class="headingEndMark"> — </span>The liver is the major metastatic site for gastrinomas, as it is with other islet cell tumors. The second most common site is bone (7 percent of patients in one series), almost all of which occur in patients who also have liver metastases [<a href="#rid44">44</a>]. The axial skeleton (spine or sacrum) is the primary site of bone metastasis, but other sites can be involved [<a href="#rid44">44</a>]. Historically, somatostatin receptor scintigraphy and MRI have been thought to be the best imaging modalities to detect these lesions; the former being preferred because extra-axial lesions can occur. Because of its greater sensitivity, 68-Ga DOTATATE PET/CT may be preferable to conventional somatostatin receptor scintigraphy, if available [<a href="#rid45">45,46</a>].</p><p>Metastatic gastrinoma is now the most common cause of morbidity and mortality in patients with Zollinger-Ellison syndrome (ZES). Unfortunately, current treatment modalities are of limited benefit. A general algorithmic approach to therapy for patients with metastatic disease is outlined in the figure  (<a class="graphic graphic_algorithm graphicRef79461" href="/d/graphic/79461.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H8"><span class="h2">Somatostatin analogs</span><span class="headingEndMark"> — </span>Somatostatin analogs like <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> are highly effective in controlling the symptoms associated with hormone hypersecretion in other pancreatic islet cell tumors that express somatostatin receptors such as glucagonomas and VIPomas, as well as carcinoid tumors; its efficacy is less predictable for gastrinomas [<a href="#rid47">47-49</a>]. Octreotide can reduce gastrin levels, and may slow tumor growth, but objective evidence of antitumor activity, specifically in ZES, is rare [<a href="#rid49">49-53</a>]. As an example, in a report of 15 patients treated with octreotide for malignant gastrinoma and progressive hepatic metastases, seven had stabilization of tumor growth, and one an objective decrease in tumor size [<a href="#rid52">52</a>]. The median duration of benefit was 25 months. In the United States, octreotide is approved for control of hormone-mediated symptoms in patients with neuroendocrine tumors.</p><p><a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">Lanreotide</a> appears to have similar clinical efficacy as <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>, and is also available in a long-acting depot form (Lanreotide-SR) [<a href="#rid47">47,54</a>]. It is approved for use in the United States based on the results of the randomized phase III CLARINET study showing a statistically significant improvement in progression-free survival in patients with nonfunctional gastroenteropancreatic neuroendocrine tumors treated with lanreotide compared to those treated with placebo [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Benefits'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Liver-directed therapy</span></p><p class="headingAnchor" id="H10"><span class="h3">Resection</span><span class="headingEndMark"> — </span>Hepatic resection is indicated for the treatment of metastatic liver disease in the absence of diffuse bilobar involvement, compromised liver function, or extensive extrahepatic metastases (eg, pulmonary, peritoneal). Although the majority of cases will not be cured by surgery, prolonged survival is often possible, given the slow-growing nature of these tumors [<a href="#rid56">56,57</a>].</p><p>In general, resection should be considered only for patients with a limited number of hepatic metastases and is most successful when undertaken with curative intent. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Hepatic artery embolization</span><span class="headingEndMark"> — </span>Liver metastases derive most of their blood supply from the hepatic artery, whereas healthy hepatocytes derive approximately 70 percent of their blood supply from the portal vein. This provides the rationale for therapeutic embolization of the hepatic artery, with the goal of inducing necrosis of the metastases with minimal damage to normal liver parenchyma.</p><p>Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is frequently applied as a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection [<a href="#rid58">58-61</a>]. Response rates, as measured by a decrease in hormonal secretion or by radiographic regression, are generally over 50 percent. Randomized trials have not yet been performed, thus it is not known with certainty if one type of embolization is preferable to another. Radioembolization with selective internal radiation therapy using Yttrium microspheres is also used, although prospective studies comparing one type of embolization with another have not been completed [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Hepatic arterial embolization'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">RFA and cryoablation</span><span class="headingEndMark"> — </span>Other approaches to the treatment of hepatic-predominant disease include radiofrequency ablation (RFA) and cryoablation, either alone or in conjunction with surgical debulking [<a href="#rid62">62-64</a>]. These procedures, which can be performed using percutaneous or laparoscopic approaches, appear to be less morbid than either hepatic resection or hepatic artery embolization. However, both techniques are applicable only to smaller lesions, and their long-term efficacy is uncertain. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Ablation'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Liver transplantation</span><span class="headingEndMark"> — </span>The number of patients with liver-isolated metastatic disease in whom orthotopic liver transplantation (OLT) has been attempted is small, and follow-up data are insufficient to judge whether complete cure has truly been achieved. The limited availability of donor organs in many regions has restricted investigation of this procedure. </p><p>Until more data become available, most clinicians consider that liver transplantation is an investigational approach for metastatic islet cell tumors, including gastrinoma. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Liver transplantation'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Chemotherapy and novel treatment approaches</span><span class="headingEndMark"> — </span>Experience with systemic chemotherapy for metastatic gastrinoma is limited. The traditional regimen of choice has been <a class="drug drug_general" data-topicid="9949" href="/d/drug information/9949.html" rel="external">streptozocin</a> and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>. Although objective response rates as high as 69 percent were initially reported for metastatic neuroendocrine tumors, [<a href="#rid65">65</a>] with decreases in endocrine hyperfunction, the true radiologic response rate is probably between 10 and 40 percent [<a href="#rid66">66,67</a>]. Uncertainty as to efficacy, as well as the toxicity of this regimen, which can include nausea, prolonged myelosuppression, and renal failure, has prevented its widespread acceptance as a standard first-line therapy for patients with metastatic neuroendocrine tumors, including gastrinoma.</p><p>Antitumor activity has also been shown for regimens containing the orally active alkylating agent <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a>. A retrospective review of 143 patients treated with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> plus temozolomide reported that 54 percent of patients experienced a radiographic response to therapy [<a href="#rid68">68</a>]. Response to chemotherapy was not influenced by O(6)-methylguanine DNA methyltransferase expression, proliferative activity, or ALT pathway activation. More recently, the results from a prospective randomized study (ECOG2211) of capecitabine plus temozolomide compared with temozolomide alone in pancreatic neuroendocrine tumors revealed similar response rates in both arms (approximately 30 percent), but the median progression-free survival was longer in the combination arm (22.7 months versus 14.4 months, HR 0.58, p=0.023) [<a href="#rid69">69</a>]. As a result of this study, use of capecitabine plus temozolomide has become routine for advanced panNET. (See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Cytotoxic chemotherapy'</a>.)</p><p>Molecularly targeted therapy with inhibitors of the mechanistic target of rapamycin (mTOR), small molecule vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors, and lutetium Lu177 dotatate peptide receptor radioligand therapy can also be used for metastatic disease [<a href="#rid70">70-74</a>]. (See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Molecularly targeted therapy'</a> and  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Peptide receptor radioligand therapy'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Mortality from gastrinomas largely depends upon whether the tumor is benign or malignant, and the extent of disease involvement. In an illustrative series, 185 patients with Zollinger-Ellison syndrome (ZES) were followed prospectively for a mean of 12.5 years [<a href="#rid23">23</a>]. The following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Liver metastases were found in 24 percent of patients at the time of diagnosis; the majority of these patients had a primary pancreatic neoplasm, and 67 percent had primary tumors that were greater than 3 cm in size.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with liver metastases had a 10-year survival of only 30 percent compared with a 15-year survival of 83 percent in those without liver metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with lymph node metastases had the same mortality as those who were free of visceral metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MEN 1 had a significantly lower rate of metastasis at the time of initial diagnosis (6 percent); their high overall survival rate (100 percent at 20 years) reflected this fact.</p><p></p><p>The level of fasting serum gastrin (FSG) at the time of initial diagnosis may provide an indication of disease extent and estimated prognosis in patients with sporadic ZES. In a follow-up report of 239 patients with ZES, the level of preoperative FSG correlated with tumor size and presence of lymph nodes and liver metastases (as found at exploration), as well as primary site (pancreas tumors associated with highest levels of FSG) [<a href="#rid75">75</a>]. The five-year survival rates for patients with mild (0 to 499 pg/mL), moderate (500 to 1000 pg/mL), or severe elevations (&gt;1000 pg/mL) of FSG were 94, 92, and 86 percent, respectively. The corresponding 10-year survival rates were 86, 87, and 73 percent.</p><p class="headingAnchor" id="H16"><span class="h1">POSTTREATMENT SURVEILLANCE</span><span class="headingEndMark"> — </span>There is limited evidence from which to make recommendations for follow-up after resection of a gastrinoma. Guidelines from the National Comprehensive Cancer Network based upon expert consensus include the following recommendations for follow-up after resection of pancreatic neuroendocrine tumor [<a href="#rid76">76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>3 to 12 months postresection – History and physical examination, serum gastrin, and abdominal multiphasic computed tomography or magnetic resonance imaging and chest CT (+/- contrast) as clinically indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term – History and physical examination with tumor markers every 6 to 12 months for a maximum of ten years. Imaging studies with abdominal multiphasic computed tomography or magnetic resonance imaging and chest CT (+/- contrast) as clinically indicated.</p><p></p><p class="headingAnchor" id="H3139910020"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Medical therapy is the current standard of care for most patients with Zollinger-Ellison syndrome (ZES) as part of the multiple endocrine neoplasia type 1 (MEN 1) syndrome (see  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a>). By contrast, we recommend that (in addition to medical therapy) patients with a sporadic gastrinoma and without evidence of metastatic spread of disease be treated with exploratory laparotomy and resection with curative intent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In addition to eliminating or at least decreasing the need for antisecretory medical therapy, successful resection of sporadic gastrinomas reduces the risk of eventual morbidity and death from metastatic spread of the tumor. (See <a class="local">'Medical management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The goal of medical management in ZES is to limit the clinical manifestations and complications of peptic ulcer disease. We recommend that patients with ZES should be started on a high dose proton pump inhibitor (eg, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> 40 mg twice daily) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Subsequent lowering of dosage without recurrence of symptoms is usually achievable. (See <a class="local">'Medical management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mortality from gastrinomas depends largely upon whether the tumor is benign or malignant, and the extent of disease involvement. Metastatic gastrinoma is the most common cause of morbidity and mortality in patients with ZES. Unfortunately, the current modalities for treatment of metastatic disease are not curative. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with limited, resectable liver-isolated metastatic gastrinoma, we recommend surgical resection of the hepatic metastases along with the primary tumor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Although the majority of cases will not be cured by surgery, given the slow-growing nature of the tumor, extended survival is sometimes possible. (See <a class="local">'Resection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other treatment options for patients with unresectable hepatic-predominant metastatic disease include bland embolization, chemoembolization, selective internal radiation therapy (radioembolization), RFA, and cryoablation. (See <a class="local">'Liver-directed therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of somatostatin analogs for patients with symptomatic metastatic gastrinoma is unpredictable, but some patients with somatostatin receptor-positive tumors may benefit. (See <a class="local">'Somatostatin analogs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other systemic therapy approaches (chemotherapy, molecularly targeted agents, and peptide receptor radioligand therapy) to control symptoms and tumor growth are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p></p><p class="headingAnchor" id="H4096720383"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Dr. Stephen E. Goldfinger, MD, for his contributions as author to prior versions of this topic review. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rossi RE, Elvevi A, Citterio D, et al. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World J Gastroenterol 2021; 27:5890.</a></li><li><a class="nounderline abstract_t">Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.</a></li><li><a class="nounderline abstract_t">Quatrini M, Castoldi L, Rossi G, et al. A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: effects of surgical and medical treatments on long-term survival. J Clin Gastroenterol 2005; 39:376.</a></li><li><a class="nounderline abstract_t">Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17:615.</a></li><li><a class="nounderline abstract_t">Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA 1994; 271:1429.</a></li><li><a class="nounderline abstract_t">Metz DC, Pisegna JR, Fishbeyn VA, et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993; 17:468.</a></li><li><a class="nounderline abstract_t">Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005; 3:39.</a></li><li><a class="nounderline abstract_t">Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006; 23:437.</a></li><li><a class="nounderline abstract_t">Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989; 97:827.</a></li><li><a class="nounderline abstract_t">Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103:1498.</a></li><li><a class="nounderline abstract_t">Norton JA, Foster DS, Ito T, Jensen RT. Gastrinomas: Medical or Surgical Treatment. Endocrinol Metab Clin North Am 2018; 47:577.</a></li><li><a class="nounderline abstract_t">Venkat PG, Longstreth GF. Gastroesophageal Reflux Disease and the Zollinger-Ellison Syndrome. Am J Gastroenterol 2022; 117:1012.</a></li><li><a class="nounderline abstract_t">Aerts M, Reynaert H. Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report. Case Rep Gastroenterol 2017; 11:616.</a></li><li><a class="nounderline abstract_t">Daniels LM, Khalili M, Morano WF, et al. Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up. World J Surg Oncol 2019; 17:213.</a></li><li><a class="nounderline abstract_t">Epelboym I, Mazeh H. Zollinger-Ellison syndrome: classical considerations and current controversies. Oncologist 2014; 19:44.</a></li><li><a class="nounderline abstract_t">Norton JA. Surgical treatment and prognosis of gastrinoma. Best Pract Res Clin Gastroenterol 2005; 19:799.</a></li><li><a class="nounderline abstract_t">Norton JA, Fraker DL, Alexander HR, Jensen RT. Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome. Ann Surg 2012; 256:509.</a></li><li><a class="nounderline abstract_t">Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg 1992; 215:8.</a></li><li><a class="nounderline abstract_t">Cockburn KC, Toumi Z, Mackie A, Julyan P. Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumours: a Systematic Literature Review. J Gastrointest Surg 2021; 25:3244.</a></li><li><a class="nounderline abstract_t">Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244:410.</a></li><li><a class="nounderline abstract_t">Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341:635.</a></li><li><a class="nounderline abstract_t">Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004; 239:617.</a></li><li><a class="nounderline abstract_t">Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108:1637.</a></li><li><a class="nounderline abstract_t">Fraker DL, Norton JA, Alexander HR, et al. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994; 220:320.</a></li><li><a class="nounderline abstract_t">Bartsch DK, Waldmann J, Fendrich V, et al. Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg 2012; 99:1234.</a></li><li><a class="nounderline abstract_t">Giovinazzo F, Butturini G, Monsellato D, et al. Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg 2013; 65:19.</a></li><li><a class="nounderline abstract_t">Máthé Z, Tagkalos E, Paul A, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation 2011; 91:575.</a></li><li><a class="nounderline abstract_t">Imamura M, Komoto I, Ota S, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011; 17:1343.</a></li><li><a class="nounderline abstract_t">Santucci N, Gaujoux S, Binquet C, et al. Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d'étude des Tumeurs Endocrines) Study. World J Surg 2021; 45:1794.</a></li><li><a class="nounderline abstract_t">Kong W, Albers MB, Manoharan J, et al. Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1. Cancers (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Jensen RT. Should the 1996 citation for Zollinger-Ellison syndrome read: "Acid-reducing surgery in, aggressive resection out"? Am J Gastroenterol 1996; 91:1067.</a></li><li><a class="nounderline abstract_t">Pisegna JR, Norton JA, Slimak GG, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992; 102:767.</a></li><li><a class="nounderline abstract_t">Ojeaburu JV, Ito T, Crafa P, et al. Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci 2011; 56:139.</a></li><li><a class="nounderline abstract_t">McArthur KE, Richardson CT, Barnett CC, et al. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. Am J Gastroenterol 1996; 91:1104.</a></li><li><a class="nounderline abstract_t">Jaskowiak NT, Fraker DL, Alexander HR, et al. Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome? Surgery 1996; 120:1055.</a></li><li><a class="nounderline abstract_t">Grobmyer SR, Vogel SB, McGuigan JE, et al. Reoperative surgery in sporadic Zollinger-Ellison Syndrome: longterm results. J Am Coll Surg 2009; 208:718.</a></li><li><a class="nounderline abstract_t">Contessa JN, Griffith KA, Wolff E, et al. Radiotherapy for pancreatic neuroendocrine tumors. Int J Radiat Oncol Biol Phys 2009; 75:1196.</a></li><li><a class="nounderline abstract_t">Strosberg J, Hoffe S, Gardner N, et al. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 2007; 85:216.</a></li><li><a class="nounderline abstract_t">Tennvall J, Ljungberg O, Ahrén B, et al. Radiotherapy for unresectable endocrine pancreatic carcinomas. Eur J Surg Oncol 1992; 18:73.</a></li><li><a class="nounderline abstract_t">Torrisi JR, Treat J, Zeman R, Dritschilo A. Radiotherapy in the management of pancreatic islet cell tumors. Cancer 1987; 60:1226.</a></li><li><a class="nounderline abstract_t">Gery B, Roussel A, Valla A. Usefulness of radiotherapy in the treatment of advanced gastrinomas. Radiother Oncol 1993; 27:259.</a></li><li><a class="nounderline abstract_t">Lee J, Choi J, Choi C, Seong J. Role of radiotherapy for pancreatobiliary neuroendocrine tumors. Radiat Oncol J 2013; 31:125.</a></li><li><a class="nounderline abstract_t">Saif MW, Ove R, Ng J, Russo S. Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions. Anticancer Res 2013; 33:2175.</a></li><li><a class="nounderline abstract_t">Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 1998; 16:1040.</a></li><li><a class="nounderline abstract_t">Deppen SA, Liu E, Blume JD, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med 2016; 57:708.</a></li><li><a class="nounderline abstract_t">Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.</a></li><li><a class="nounderline abstract_t">Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93:1468.</a></li><li><a class="nounderline abstract_t">Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8:1041.</a></li><li><a class="nounderline abstract_t">Guarnotta V, Martini C, Davì MV, et al. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? Endocrine 2018; 60:15.</a></li><li><a class="nounderline abstract_t">Saijo F, Naito H, Funayama Y, et al. Octreotide in control of multiple liver metastases from gastrinoma. J Gastroenterol 2003; 38:905.</a></li><li><a class="nounderline abstract_t">Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94:331.</a></li><li><a class="nounderline abstract_t">Burgess JR, Greenaway TM, Parameswaran V, Shepherd JJ. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis. Cancer 1999; 86:2154.</a></li><li><a class="nounderline abstract_t">Massironi S, Cavalcoli F, Elvevi A, et al. Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. Endocrine 2022; 75:942.</a></li><li><a class="nounderline abstract_t">Gaztambide S, Vazquez JA. Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma. J Endocrinol Invest 1999; 22:144.</a></li><li><a class="nounderline abstract_t">Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371:224.</a></li><li><a class="nounderline abstract_t">Zhang XF, Beal EW, Weiss M, et al. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis. J Surg Oncol 2018; 117:171.</a></li><li><a class="nounderline abstract_t">Spolverato G, Bagante F, Aldrighetti L, et al. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surg 2017; 21:2039.</a></li><li><a class="nounderline abstract_t">Chen JX, Rose S, White SB, et al. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. Cardiovasc Intervent Radiol 2017; 40:69.</a></li><li><a class="nounderline abstract_t">Pericleous M, Caplin ME, Tsochatzis E, et al. Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes. Asia Pac J Clin Oncol 2016; 12:61.</a></li><li><a class="nounderline abstract_t">Havens SJ, Hruby PM, Margalit E. Listeria monocytogenes panophthalmitis: a novel strain follows a virulent course. Retin Cases Brief Rep 2013; 7:409.</a></li><li><a class="nounderline abstract_t">de Mestier L, Zappa M, Hentic O, et al. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord 2017; 18:459.</a></li><li><a class="nounderline abstract_t">Deol ZK, Frezza E, DeJong S, Pickleman J. Solitary hepatic gastrinoma treated with laparoscopic radiofrequency ablation. JSLS 2003; 7:285.</a></li><li><a class="nounderline abstract_t">Fairweather M, Swanson R, Wang J, et al. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Ann Surg Oncol 2017; 24:2319.</a></li><li><a class="nounderline abstract_t">Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg 2015; 19:2273.</a></li><li><a class="nounderline abstract_t">Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303:1189.</a></li><li><a class="nounderline abstract_t">Prakash L, Bhosale P, Cloyd J, et al. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2017; 21:155.</a></li><li><a class="nounderline abstract_t">Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762.</a></li><li><a class="nounderline abstract_t">Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23:759.</a></li><li><a class="nounderline abstract_t">Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal of Clinical Oncology 2018; 36:4004.</a></li><li><a class="nounderline abstract_t">Leimer M, Kurtaran A, Smith-Jones P, et al. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 1998; 39:2090.</a></li><li><a class="nounderline abstract_t">Grozinsky-Glasberg S, Barak D, Fraenkel M, et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011; 117:1377.</a></li><li><a class="nounderline abstract_t">Brabander T, Van der Zwan WA, Teunissen JJ, et al. Long-term efficacy, survival and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017.</a></li><li><a class="nounderline abstract_t">Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514.</a></li><li><a class="nounderline abstract_t">Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501.</a></li><li><a class="nounderline abstract_t">Berger AC, Gibril F, Venzon DJ, et al. Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome. J Clin Oncol 2001; 19:3051.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on May 22, 2020).</li></ol></div><div id="topicVersionRevision">Topic 2584 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34629807" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598474" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of patients with Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15815204" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: effects of surgical and medical treatments on long-term survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080607" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7513768" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8362529" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15645403" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16423003" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2777040" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1426868" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30098717" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gastrinomas: Medical or Surgical Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35347099" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gastroesophageal Reflux Disease and the Zollinger-Ellison Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29430219" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Disease Control on Lanreotide Autogel®120 mg in a Patient with Metastatic Gastrinoma: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31818296" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24319020" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Zollinger-Ellison syndrome: classical considerations and current controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253901" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Surgical treatment and prognosis of gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22868363" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1531004" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34506015" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumours: a Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926567" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Surgery increases survival in patients with gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460814" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Surgery to cure the Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082965" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7768367" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7916560" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22864882" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23417896" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21200365" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21455335" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33649917" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d'étude des Tumeurs Endocrines) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35454834" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651148" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Should the 1996 citation for Zollinger-Ellison syndrome read: "Acid-reducing surgery in, aggressive resection out"?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1537514" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20725788" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mechanism of acid hypersecretion post curative gastrinoma resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651153" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957495" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19476823" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reoperative surgery in sporadic Zollinger-Ellison Syndrome: longterm results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19327905" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Radiotherapy for pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17541257" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1310647" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Radiotherapy for unresectable endocrine pancreatic carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3040209" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Radiotherapy in the management of pancreatic islet cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7692475" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Usefulness of radiotherapy in the treatment of advanced gastrinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24137557" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Role of radiotherapy for pancreatobiliary neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23645772" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9508189" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26769865" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26712231" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732927" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Slow-release lanreotide treatment in endocrine gastrointestinal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402179" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29019150" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564638" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Octreotide in control of multiple liver metastases from gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11900219" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10570446" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34716542" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195383" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25014687" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lanreotide in metastatic enteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940257" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28744737" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27738818" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26663886" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25383817" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Listeria monocytogenes panophthalmitis: a novel strain follows a virulent course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28975561" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Liver transarterial embolizations in metastatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14558723" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Solitary hepatic gastrinoma treated with laparoscopic radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28303430" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341823" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6252466" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27634306" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15570077" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27552969" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867148" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21425137" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28428192" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term efficacy, survival and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21306238" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Everolimus for advanced pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21306237" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11408501" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
